文献速递血栓与止血

疑似肝素诱导性血小板减少症患者的大出血风险

The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia.
PubMed 文献 · J Thromb Haemost · 2019-08-12

该回顾性分析纳入310例疑似肝素诱导性血小板减少症(HIT)患者,比较不同HIT状态和替代抗凝暴露组的大出血累积发生率。结果显示大出血在各组均常见(HIT+Tx+组35.7%、HIT-Tx+组44.0%、HIT-Tx-组37.3%),HIT+患者并未受到保护。

要点

  • 疑似HIT患者中大出血常见,HIT+Tx+组为35.7%、HIT-Tx+组为44.0%、HIT-Tx-组为37.3%。
  • 首 次大出血事件时间在各组间无显著差异(P = .24)。
  • ICU入住、血小板计数<25×10^9/L和肾功能不全都与了大出血风险增加相关。

核心结论

  • 在疑似HIT患者中,无论HIT状态如何,大出血均常见;与假设相反,HIT+患者并未免受大出血保护。

研究设计与样本

  • 对来自宾夕法尼亚大学医院及其附属社区医院的310例疑似HIT患者进行回顾性分析。

主要发现

  • 大出血发生率:HIT+Tx+组35.7%、HIT-Tx+组44.0%、HIT-Tx-组37.3%。
  • 首次大出血事件时间在各组间无差异(P = .24)。
  • 与大出血风险增加相关的因素:ICU入住(HR 2.24,95%CI 1.44-3.47)、血小板计数<25×10^9/L(HR 2.13,95%CI 1.10-4.12)、肾功能不全(HR 1.56,95%CI 1.06-2.27)。
  • 新发/进展性血栓发生率:HIT+Tx+组35.7%、HIT-Tx+组13.8%、HIT-Tx-组9.3%。
  • 30天死亡率在三组间相似:HIT+Tx+组26.2%、HIT-Tx+组34.5%、HIT-Tx-组26.7%(P = .34)。

临床怎么用

  • 在疑似HIT患者中,需关注大出血风险,尤其是合并ICU入住、血小板计数<25×10^9/L或肾功能不全者。
  • 对疑似HIT患者的管理决策需基于对出血风险的更好理解。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The presence of a hypercoagulable disorder such as heparin-induced thrombocytopenia (HIT) may protect against anticoagulant-associated bleeding. OBJECTIVES: To determine the incidence of major bleeding in patients with suspected HIT. METHODS: We performed a retrospective analysis of 310 patients suspected of having HIT from the Hospital of the University of Pennsylvania and an affiliated community hospital. We compared the cumulative incidence of major bleeding following suspicion for HIT by ultimate HIT status (HIT+ or HIT-) and exposure to an alternative anticoagulant (Tx+ or Tx-). Secondary outcomes included the incidence of new/progressive thrombosis and 30-day mortality. RESULTS: The incidence of major bleeding was high in the HIT+Tx+, HIT- Tx+, and HIT-Tx- groups (35.7%, 44.0%, and 37.3%, respectively). The time to first major bleeding event did not differ between groups (P = .24). Factors associated with increased risk of major bleeding included intensive care unit admission (HR 2.24, 95% CI 1.44-3.47), platelet count < 25 × 109 /L (HR 2.13, 1.10-4.12), and renal dysfunction (HR 1.56, 1.06-2.27); 35.7% of HIT+Tx+, 13.8% HIT-Tx+, and 9.3% of HIT-Tx- patients experienced new or progressive thrombosis. Mortality was similar among the three groups (26.2% HIT+Tx+, 34.5% HIT-Tx+, and 26.7% of HIT-Tx- [P = .34]). CONCLUSIONS: Among patients with suspected HIT, major bleeding was common regardless of HIT status. Contrary to our hypothesis, HIT+ patients were not protected from major bleeding. A better understanding of bleeding risk is needed to inform management decisions in patients with suspected HIT.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Pishko AM, Lefler DS, Gimotty P, et al. The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia. J Thromb Haemost. 2019. PMID: 31350937. doi:10.1111/jth.14587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。